Expert Answer
Is heart disease driven by inflammation or by cholesterol?
Quick Answer
This is the most persistent disagreement in our dataset. Hyman's guests keep arguing that high cholesterol is a downstream signal of insulin resistance and inflammation, so chasing LDL with a statin treats the number and misses the cause. Attia keeps answering that ApoB, the count of cholesterol-carrying particles, is itself causal: the particle has to enter the artery wall for plaque to form, and lifetime exposure tracks linearly with mortality. The two positions are not symmetrical. One says the marker is a symptom, the other says the marker is the mechanism. Where they do converge is that ApoB beats a standard lipid panel, and that statins are over-prescribed in some groups. This is a decision to make with a physician who will measure ApoB.
What the Panel Says
The most consistent position in the dataset, made across many episodes. ApoB is a necessary causal driver, not a passive marker, and lifetime LDL exposure tracks linearly with mortality in mendelian randomization. He also argues for driving ApoB well down early, on the view that it would largely take atherosclerosis off the table.
Has run the inflammation-first argument three times with three different guests, from Aseem Malhotra's metabolic reset through Cindy Geyer to cardiovascular surgeon Jeremy London. The frame is that heart disease is an inflammatory, insulin-driven process.
Sits between them. With Ronald Krauss she grants that statins carry a real type-2 diabetes risk, especially in women, and get over-prescribed, without conceding the causation argument.
With Chris Palmer, makes the narrower version, that being thin is not the same as being metabolically healthy, and that people who look fine routinely carry bad markers.
No direct stance on the causation question in the analyzed videos.
How this moved
3 updates since June 2026. Each one is a dated statement from a named expert, timecoded to the video.
-
Latest Jeremy London, on Mark Hyman's show
A surgeon with an ApoB of 180 who looked healthy
The most concrete entry on the record, and the one that cuts against the show's own framing. A cardiovascular surgeon who ate well and looked healthy reports his own ApoB at 180, and says a standard lipid panel would never have shown it. The inflammation-first case is being made with the measurement the other side asked for.
on the record @ 10:46 -
Cindy Geyer, on Mark Hyman's show
Restated with a second guest, and answered again
Same argument, different clinician. Chasing LDL with statins treats the number and misses an inflammatory, insulin-driven process. This is where the two sides find their one point of agreement, that the number worth watching is ApoB rather than total LDL cholesterol, even while they disagree about whether that number is a cause or a symptom.
on the record @ 03:05 -
Aseem Malhotra, on Mark Hyman's show
Treat the cause, not the number
The opening position. High cholesterol is mostly a downstream signal of insulin resistance and inflammation, so the move is a metabolic reset rather than a statin. Attia's corpus answered it twice the same week, once on particle count being causal in itself and once on lifetime LDL exposure tracking linearly with mortality.
on the record @ 01:49
Nobody has answered
Whether lowering ApoB in someone with no metabolic dysfunction changes outcomes. That is the exact question separating the two camps and neither has answered it on the record. Nor has anyone here addressed the reverse, whether fixing insulin resistance lowers ApoB enough to matter on its own. Bryan Johnson has no coverage of the question, and Patrick has stayed on the statin side-effect argument rather than the causation one.
Detailed Answer
Two of these experts have been arguing past each other for months, and the argument is worth understanding because it changes what you would test and what you would do about the result.
The inflammation-first case, which Hyman has now made with three separate guests, is that cholesterol rises because something upstream is wrong. Insulin resistance and chronic inflammation are the disease; the lipid panel is the smoke. On that reading, prescribing a statin to lower the number is treating a readout while the process underneath continues.
The particle case, which is Attia's, is not the mirror image of that. He is not arguing that inflammation is irrelevant. He is arguing that ApoB is mechanically required: the particle has to cross into the artery wall for plaque to form at all, which makes the count causal rather than correlated.
The evidence he leans on is mendelian randomization, where lifetime LDL exposure tracks linearly with mortality, and genetics rather than lifestyle sets the exposure.
Where they actually agree
Both sides have landed on ApoB as the number to measure, and against the standard lipid panel. Tom Dayspring's account on Attia's show is that the field standardized on ApoB because the assay is consistent across labs and cheap. Hyman's guest Jeremy London arrives at the same place from the other direction, reporting his own ApoB at 180 while looking healthy and eating well, and saying a standard panel would have missed it.
Both sides also accept that statins are over-prescribed in some groups. Patrick, with Ronald Krauss, grants a real type-2 diabetes risk, especially in women.
The part that is genuinely unresolved
Nobody in this dataset has answered whether lowering ApoB in a metabolically healthy person changes their outcome. That is the precise question the disagreement turns on. Until someone does, the practical convergence is smaller than it looks: measure ApoB, because both camps want that number, and take the interpretation to a physician rather than to a podcast.
Related Questions
Is high cholesterol just a symptom of insulin resistance?
That is Hyman's position, argued with Aseem Malhotra, Cindy Geyer and Jeremy London. Attia's counter is that ApoB is mechanically necessary for plaque to form, so the particle count is causal rather than a readout of something else. Both agree metabolic health matters; they disagree about whether the lipid number is a cause.
Which number should I actually measure?
Both sides say ApoB rather than a standard lipid panel. Dayspring, on Attia's show, explains the field standardized on it because the assay is consistent across labs and inexpensive. Hyman's guest Jeremy London reports his own ApoB at 180 while a standard panel looked unremarkable.
Are statins over-prescribed?
Patrick, with Ronald Krauss, grants that they carry a real type-2 diabetes risk, especially in women, and that they are over-prescribed in some groups. That is separate from the causation argument, and nobody in the dataset says statins do not lower ApoB.
Does large fluffy LDL mean I am safe?
Jim Otvos, who built the NMR test that made particle size measurable, told Attia that small dense LDL looks more atherogenic mainly because those people carry more particles. The risk tracks the count, not the size. Hyman disagrees and treats small dense particles as the biggest driver.
More Questions About Heart Disease & ApoB
Precis Pro
Ask the experts anything
The answer above is the whole answer — every expert's position, where they disagree, and the timecode behind each one.
Pro adds
- Expert-by-expert breakdowns on any topic in the corpus
- Chat across 3,700+ expert videos
- A timestamp on every claim, so you can check it yourself
$9/mo · Cancel anytime